- First quarter 2025 net sales of Qelbree® increased 44% to $64.7 million, compared to the same period in 2024.
- First quarter 2025 net sales of GOCOVRI® increased 16% to $30.7 million, compared to the same period in 2024.
- First quarter 2025 total revenues increased 4% to $149.8 million, compared to the same period in 2024. First quarter 2025 total revenues excluding Trokendi XR® and Oxtellar XR® net sales (non-GAAP)(1) increased 26% compared to the first quarter of 2024.
- First quarter 2025 operating loss of $(10.3) million, compared to operating loss of $(3.2) million in 2024. First quarter adjusted operating earnings (non-GAAP)(1) increased 16% to $25.9 million.
- ONAPGO™ (apomorphine hydrochloride) launched in the U.S. in April 2025.
- The Company reiterates full year 2025 financial guidance.
ROCKVILLE, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the first quarter 2025 and associated Company developments.
“Our first quarter results reflect, once again, double-digit revenue growth from our core products, as well as strong growth in adjusted operating earnings,” said Jack Khattar, President and CEO of Supernus. “In addition, we are pleased to be bringing ONAPGO to market, another growth driver for our business. ONAPGO represents a novel approach for adults with Parkinson’s disease who are experiencing motor fluctuations.”
Commercial Highlights
- Total IQVIA prescriptions(2) for Qelbree were 214,908 for the first quarter 2025, an increase of 22% compared to the same period in the prior year. For March 2025, total monthly prescriptions reached an all-time high of 75,277. Qelbree continues to expand its base of prescribers, with approximately 34,416 prescribers in the first quarter of 2025, up from 27,902 prescribers in the same period last year.
- In April 2025, the Company launched ONAPGO, the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease. Initial physician response is encouraging based on very early activity in the launch.
Product Pipeline Update
SPN-817 – Novel first-in-class highly selective AChE inhibitor for epilepsy
- The Phase 2b randomized, double-blind, placebo-controlled study of 3mg and 4mg twice daily doses is ongoing with a targeted enrollment of approximately 258 adult patients with treatment resistant focal seizures.
SPN-820 – Novel first-in-class molecule that increases mTORC1 mediated synaptic function for depression
- The Company plans to initiate a follow-on Phase 2b multi-center, randomized, double-blind, placebo-controlled trial in approximately 200 adults with major depressive disorder (MDD). The study will examine the safety and tolerability of SPN-820 2400 mg given intermittently (twice weekly) as an adjunctive treatment to the current baseline antidepressant therapy, as well as assess the rapid onset of improvement in depressive symptoms.
SPN-443 – Novel stimulant for ADHD/CNS
- The Company completed a Phase 1 pharmacokinetic study of two oral formulations in healthy adults. Both formulations of SPN-443 showed adequate bioavailability and were well tolerated. The Company expects to disclose a lead indication for the product candidate by the end of 2025.
Financial Highlights
This section includes information on non-GAAP financial measures. See “Non-GAAP Financial Information” section for information on non-GAAP financial measures. In addition, a reconciliation of applicable GAAP to non-GAAP financial information is included at the end of this press release.
Revenues
The following table provides information regarding total revenues (dollars in millions):
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | Change % | ||||||
| (unaudited) | ||||||||
| Net product sales | ||||||||
| Qelbree | $ | 64.7 | $ | 45.1 | 44 | % | ||
| GOCOVRI | 30.7 | 26.5 | 16 | % | ||||
| APOKYN | 15.0 | 16.7 | (10 | )% | ||||
| Trokendi XR | 12.8 | 16.0 | (20 | )% | ||||
| Oxtellar XR | 10.2 | 26.9 | (62 | )% | ||||
| Other(3) | 8.6 | 7.2 | 19 | % | ||||
| Total net product sales | 142.0 | 138.4 | 3 | % | ||||
| Royalty, licensing and other revenues(4) | 7.8 | 5.2 | 51 | % | ||||
| Total revenues | $ | 149.8 | $ | 143.6 | 4 | % | ||
| Total revenues excluding Trokendi XR and Oxtellar XR net sales (non-GAAP)(1) | $ | 126.8 | $ | 100.7 | 26 | % | ||
Other Financial Highlights
- Operating loss was $(10.3) million for the three months ended March 31, 2025, compared to operating loss of $(3.2) million for the same period in 2024. The change was primarily due to higher contingent consideration loss, mainly related to the achievement of ONAPGO-related milestones, and higher selling and marketing expenses.
- Adjusted operating earnings (non-GAAP) were $25.9 million for the three months ended March 31, 2025, compared to $22.3 million for the same period in 2024.
- Net loss and diluted loss per share were $(11.8) million and $(0.21) for the three months ended March 31, 2025, compared to net earnings and diluted earnings per share of $0.1 million and $0.00 for the three months ended March 31, 2024.
- At March 31, 2025, cash, cash equivalents, and current and long-term marketable securities were approximately $463.6 million compared to $453.6 million as of December 31, 2024. This increase was primarily due to cash generated from operations partially offset by the $25.0 million payment of ONAPGO-related milestone in the first quarter of 2025.
Full Year 2025 Financial Guidance
For the full year 2025, the Company reiterates its full year financial guidance as set forth below (dollars in millions):
| Current Guidance (as of February 25, 2025) | |
| Total revenues (includes approximately $65 million - $75 million of Trokendi XR and Oxtellar XR)(5)(6) | $600 - $630 |
| Combined R&D and SG&A expenses | $435 - $460 |
| Operating earnings (loss) | $(15) - $10 |
| Adjusted operating earnings (non-GAAP)(1) | $105 - $130 |
Non-GAAP Financial Information
This press release contains financial measures that present financial information which do not comply with United States generally accepted accounting principles (GAAP). The non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, or superior to measures prepared in accordance with GAAP. Non-GAAP adjusted operating earnings on a historical and projected basis adjusts for non-cash share-based compensation expense, depreciation and amortization, intangible asset impairment charges and changes to fair value of contingent consideration, and for factors that are unusual, non-recurring or unpredictable, and excludes those costs, expenses, and other specified items presented in the reconciliation tables in this press release. In addition to non-GAAP adjusted operating earnings, we also present total revenues excluding net sales of Trokendi XR (GAAP) and Oxtellar XR (GAAP), which is a non-GAAP measure and is calculated as total revenues (GAAP) less net product sales of Trokendi XR (GAAP) and Oxtellar XR (GAAP). Beginning in the year a product loses exclusivity due to generic entrants, we generally do not expect net product sales of such products to constitute a significant part of our revenue in the future. We believe that the use of non-GAAP financial measures provides useful supplemental information to management, investors, analysts and others regarding the Company’s revenue and results of operations and assist management, investors, analysts, and others in understanding and evaluating our revenue growth and the performance of the business.
There are limitations associated with the use of non-GAAP financial measures and therefore comparability may be limited. These limitations include: non-GAAP financial measures that may not be entirely comparable to similarly titled measures used by other companies; these may not reflect all items of income and expense, as applicable, that affect our operations; there may be potential differences among calculation methodologies; these may differ from the non-GAAP information used by other companies, including peer companies. We mitigate these limitations by reconciling the non-GAAP financial measure to the most comparable GAAP financial measure. Investors are encouraged to review the reconciliation. The Company’s 2025 financial guidance is also being provided on both a GAAP and a non-GAAP basis.
End Notes
____________________________________
(1) See the section titled “Non-GAAP Financial Information” for information about this non-GAAP financial measure. A reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure is included at the end of this press release.
(2) IQVIA data restatement July 1, 2024.
(3) Includes net product sales of MYOBLOC®, XADAGO® and Osmolex ER®.
(4) Royalty, licensing, and other revenues include royalties on generic Trokendi XR, Oxtellar XR, other licensed products and intellectual property.
(5) Includes net product sales and royalty, licensing, and other revenue.
(6) Reflects continued generic erosion of Trokendi XR and generic erosion of Oxtellar XR beginning in September 2024.
Conference Call Details
Supernus will host a conference call and webcast today, May 6, 2025, at 4:30 p.m. Eastern Time to discuss these results. A live webcast will be available in the Events & Presentations section of the Company’s Investor Relations website www.supernus.com/investors.
Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.
Following the live call, a replay will be available on the Company's Investor Relations website www.supernus.com/investors. The webcast will be available on the Company’s website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for epilepsy, depression, and other CNS disorders.
For more information, please visit www.supernus.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for each of its products and the products of its subsidiaries; the Company’s ability to increase its net revenue from its products and the products of its subsidiaries; the Company’s ability to commercialize its products and the products of its subsidiaries; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates; the Company’s ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; changes to laws and regulations applicable to our industry, the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs; and other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
| Supernus Pharmaceuticals, Inc. | |||||||
| Consolidated Balance Sheets | |||||||
| (in thousands, except share and per share data) | |||||||
| March 31, | December | ||||||
| 2025 | 2024 | ||||||
| (unaudited) | |||||||
| Assets | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 115,848 | $ | 69,331 | |||
| Marketable securities | 347,742 | 384,281 | |||||
| Accounts receivable, net | 145,640 | 142,077 | |||||
| Inventories, net | 49,423 | 54,293 | |||||
| Prepaid expenses and other current assets | 28,931 | 36,088 | |||||
| Total current assets | 687,584 | 686,070 | |||||
| Property and equipment, net | 11,338 | 11,545 | |||||
| Intangible assets, net | 502,126 | 521,912 | |||||
| Goodwill | 117,019 | 117,019 | |||||
| Other assets | 29,223 | 31,527 | |||||
| Total assets | $ | 1,347,290 | $ | 1,368,073 | |||
| Liabilities and stockholders’ equity | |||||||
| Current liabilities | |||||||
| Accounts payable and accrued liabilities | $ | 76,891 | $ | 76,352 | |||
| Accrued product returns and rebates | 170,133 | 168,705 | |||||
| Contingent consideration, current portion | 30,000 | 47,340 | |||||
| Other current liabilities | 4,748 | — | |||||
| Total current liabilities | 281,772 | 292,397 | |||||
| Operating lease liabilities, long-term | 26,368 | 27,382 | |||||
| Deferred income tax liabilities, net | 981 | 4,961 | |||||
| Other liabilities | 7,464 | 7,600 | |||||
| Total liabilities | 316,585 | 332,340 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ equity | |||||||
| Common stock, $0.001 par value; 130,000,000 shares authorized; 55,989,248 and 55,743,095 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 56 | 56 | |||||
| Additional paid-in capital | 486,209 | 479,440 | |||||
| Accumulated other comprehensive loss, net of tax | (159 | ) | (189 | ) | |||
| Retained earnings | 544,599 | 556,426 | |||||
| Total stockholders’ equity | 1,030,705 | 1,035,733 | |||||
| Total liabilities and stockholders’ equity | $ | 1,347,290 | $ | 1,368,073 | |||
| Supernus Pharmaceuticals, Inc. | |||||||
| Consolidated Statements of Earnings (Loss) | |||||||
| (in thousands, except share and per share data) | |||||||
| Three Months Ended March 31, | |||||||
| 2025 | 2024 | ||||||
| (unaudited) | |||||||
| Revenues | |||||||
| Net product sales | $ | 141,988 | $ | 138,461 | |||
| Royalty, licensing and other revenues | 7,836 | 5,183 | |||||
| Total revenues | 149,824 | 143,644 | |||||
| Costs and expenses | |||||||
| Cost of goods sold(a) | 15,763 | 16,309 | |||||
| Research and development | 26,927 | 24,930 | |||||
| Selling, general and administrative | 89,944 | 86,516 | |||||
| Amortization of intangible assets | 19,786 | 20,137 | |||||
| Contingent consideration loss (gain) | 7,660 | (1,095 | ) | ||||
| Total costs and expenses | 160,080 | 146,797 | |||||
| Operating loss | (10,256 | ) | (3,153 | ) | |||
| Other income (expense) | |||||||
| Interest and other income, net | 4,425 | 3,396 | |||||
| Total other income (expense), net | 4,425 | 3,396 | |||||
| Earnings (loss) before income taxes | (5,831 | ) | 243 | ||||
| Income tax expense | 5,996 | 119 | |||||
| Net earnings (loss) | $ | (11,827 | ) | $ | 124 | ||
| Earnings (Loss) per share | |||||||
| Basic | $ | (0.21 | ) | $ | — | ||
| Diluted | $ | (0.21 | ) | $ | — | ||
| Weighted average shares outstanding | |||||||
| Basic | 55,864,692 | 54,801,748 | |||||
| Diluted | 55,864,692 | 55,626,663 | |||||
____________________________________
(a) Excludes amortization of intangible assets.
| Supernus Pharmaceuticals, Inc. | ||||||||||
| Reconciliations of GAAP to Non-GAAP Financial Information | ||||||||||
| (unaudited) | ||||||||||
| Reconciliation of GAAP Total revenues to Non-GAAP Total revenues excluding Trokendi XR and Oxtellar XR net sales | ||||||||||
| An itemized reconciliation between total revenues on a GAAP basis and Total revenues excluding Trokendi XR and Oxtellar XR net sales, a non-GAAP measure, is as follows (dollars in millions): | ||||||||||
| Three Months Ended March 31, | ||||||||||
| 2025 | 2024 | Change % | ||||||||
| Total revenues (GAAP)(1) | $ | 149.8 | $ | 143.6 | 4 | % | ||||
| Adjustments: | ||||||||||
| Trokendi XR net product sales | (12.8 | ) | (16.0 | ) | (20 | )% | ||||
| Oxtellar XR net product sales | (10.2 | ) | (26.9 | ) | (62 | )% | ||||
| Total revenues excluding Trokendi XR and Oxtellar XR net sales (non-GAAP)(1) | $ | 126.8 | $ | 100.7 | 26 | % | ||||
___________________________________________
(1) Includes net product sales and royalty, licensing, and other revenues.
Reconciliation of GAAP Operating Loss to Non-GAAP Adjusted Operating Earnings
An itemized reconciliation between operating loss on a GAAP basis and adjusted operating earnings on a non-GAAP basis is as follows (dollars in millions):
| Three Months Ended March 31, | |||||||
| 2025 | 2024 | ||||||
| Operating loss - As Reported (GAAP) | $ | (10.3 | ) | $ | (3.2 | ) | |
| Adjustments: | |||||||
| Amortization of intangible assets | 19.8 | 20.1 | |||||
| Share-based compensation | 8.1 | 5.9 | |||||
| Contingent consideration loss (gain) | 7.7 | (1.1 | ) | ||||
| Depreciation | 0.6 | 0.6 | |||||
| Operating earnings - As Adjusted (non-GAAP) | $ | 25.9 | $ | 22.3 | |||
Non-GAAP adjusted operating earnings adjusts for non-cash items including amortization of intangible assets, share-based compensation expense, change in fair value of contingent consideration, intangible assets impairment charges, and depreciation.
Reconciliation of Full Year 2025 Financial Guidance - GAAP Operating Earnings (Loss) to Non-GAAP Adjusted Operating Earnings
An itemized reconciliation between projected operating earnings (loss) on a GAAP basis for the full year 2025 and projected adjusted operating earnings on a non-GAAP basis for the full year 2025 is as follows (dollars in millions):
| Current Guidance (as of February 25, 2025) | |
| Operating earnings (loss) - GAAP | $(15) - $10 |
| Adjustments: | |
| Amortization of intangible assets | $81 - $84 |
| Share-based compensation | $30 - $34 |
| Contingent consideration loss | $7 - $8 |
| Depreciation | $2 - $3 |
| Operating earnings - As Adjusted (non-GAAP) | $105 - $130 |
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
ICR Healthcare
(443) 213-0505
peter.vozzo@icrhealthcare.com
